Table 5.
Radiotheranostic agents in hematological cancers, based on monoclonal antibodies.
| Name | Ag | Disease | Isotope | In vitro/vivo | Ref | |
|---|---|---|---|---|---|---|
| Diagnostic | Therapeutic | |||||
| Tositumomab (Bexxar) | CD20 | B-cell NHL | 131I | 131I | Both | (82) |
| ibritumomab tiuxetan (Zevalin) | CD20 | NHL/DLBCL/MCL/FL | 90Y | 90Y | Both | (15) |
| Epratuzumab tetraxetan | CD22 | NHL/ALL | 90Y | 90Y | Both | (83) |
| HuM195 (lintuzumab) | CD33 | AML/myeloid leukemia | 131I, 90Y | 131I, 213Bi, 90Y, 227Th, 225Ac, 111In | Both | (14, 84–87) |
| Daratumumab | CD38 | MM | 89Zr/64Cu | 212Pb, 225Ac | Both | (88–91) |
| MB-1 | CD37 | lymphoma | 131I | 131I | Both | (92) |
| 9E7.4 | CD138 | MM | / | 213Bi/177Lu | Both | (93) |
| B-B4 | CD138 | MM | 131I | 131I | Both | (94) |
| BC8 | CD45 | Myeloablation | 131I | 131I | Both | (95) |
| CSL360 | CD123 | AML | 111In | 111In | Both | (96) |
| Anti-CD66 antibody | CD66 | AML/MDS | / | 88Re/90Y | In vivo | (97) |
| lilotomab | Cd37 | NHL/lymphoma | 177Lu | 177Lu | Both | (98) |
| IIIA4 | EphA3 | pre-B-ALL | / | 213Bi | Both | (99) |
| Daclizumab | IL-2 receptor | ALL-T | 90Y | Both | (100) | |
| brentuximab vedotin | CD30 | Lymphoma | 89Zr | both | (101) | |